Showing 2461-2470 of 5644 results for "".
- ForeseeHome AMD Home Monitoring Real-World Data Analysis Demonstrates Substantial Benefit for Patients’ Visionhttps://modernod.com/news/foreseehome-amd-home-monitoring-real-world-data-analysis-demonstrates-substantial-benefit-for-patients-vision/2479053/Real-world data on the performance of the ForeseeHome AMD Monitoring Program, a home-based diagnostic that helps detect the conversion from intermediate dry to wet age-related macular degeneration (AMD), was recently published in the Journal of Clinical Medicine as part of the “Diagnosis,
- AffaMed Therapeutics Completes $170 Million Series B Financing to Further Development of Ophthalmic and Neuroscience Pipelinehttps://modernod.com/news/affamed-therapeutics-completes-170-million-series-b-financing-to-further-development-of-ophthalmic-and-neuroscience-pipeline/2479029/AffaMed Therapeutics announced the completion of over $170 million in Series B financing. Proceeds from the financing will be used to advance clinical development of AffaMed’s pipeline of innovative therapeutic candidates, progress business development and partnering activities, and support
- Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 Drug Candidate in Greater Chinahttps://modernod.com/news/tarsus-pharmaceuticals-and-lianbio-announce-strategic-partnership-to-develop-and-commercialize-tp-03-drug-candidate-in-greater-china/2479026/Tarsus Pharmaceuticals and LianBio announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 is a first-in-class investigational therapeutic in development for the treatment of Demodex blepharitis and M
- Neurolens Announces the Launch of the nMD2 Measurement Devicehttps://modernod.com/news/neurolens-announces-the-launch-of-the-nmd2-measurement-device/2479022/Neurolens has announced the launch of the neurolens Measurement Device, Gen 2 (nMD2), an objective and repeatable way to measure binocular vision, or more specifically, eye alignment. Employing over 10,000 data points per patient, the eye tracking system can identify eye misalignment as small as
- Steady Growth, New Technologies Will Drive Retinal Surgery Device Market to $1.36 Billion by 2026https://modernod.com/news/steady-growth-new-technologies-will-drive-retinal-surgery-device-market-to-1-36-billion-by-2026/2479005/The retinal surgical device market is expected to total more than $1.14 billion in 2021, with revenue rising to nearly $1.36 billion in 2026, according to a Market Scope report. Retina surgery device sales are driven almost entirely by vitrectomy, a procedure which involves removal of the
- HK Scientist Develops Retinal Scan Technology to Identify Early Childhood Autismhttps://modernod.com/news/hk-scientist-develops-retinal-scan-technology-to-identify-early-childhood-autism/2478987/A Hong Kong scientist has developed a method to use machine learning and artificial intelligence to scan retinas of children as young as six to detect early autism or the risk of autism and hopes to develop a commercial product this year, according to a Reuters
- NovaSight Announces First Pivotal Study for Lazy-Eye Digital Treatment Against Gold Standard Patchinghttps://modernod.com/news/novasight-announces-first-pivotal-study-for-lazy-eye-digital-treatment-against-gold-standard-patching/2478980/Israeli startup NovaSight has announced that it is running a large, pivotal multicenter randomized controlled trial to assess the safety and effectiveness of an eye-tracking-based treatment for amblyopia (lazy eye). This is the first pivotal study of its kind in children against the gold standard
- Visus Therapeutics Announces FDA Acceptance of IND to Proceed With Clinical Development of Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/Visus Therapeutics announced that the FDA has accepted the company’s investigational new drug application (IND) to proceed with the clinical development program for Brimochol, the company’s lead investigational asset. Under this IND, Visus will initiate its planned phase 2 clinical trial in the U
- Lilly’s Bamlanivimab, Etesevimab Cut Hospitalizations, Deaths in High-Risk COVID-19 Patientshttps://modernod.com/news/lillys-bamlanivimab-etesevimab-cut-hospitalizations-deaths-in-high-risk-covid-19-patients/2478961/Eli Lilly reported new phase 3 results demonstrating that the antibody cocktail containing bamlanivimab and etesevimab significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with SARS-CoV-2 infection. “These positive results reinforce our
- Adverum Announces Shortened Timelines and Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMDhttps://modernod.com/news/adverum-announces-shortened-timelines-and-clear-development-path-for-advm-022-intravitreal-gene-therapy-in-wet-amd/2478955/Adverum Biotechnologies announced that it has gained alignment with the FDA on the clinical development path for ADVM-022, an investigational single, in-office intravitreal (IVT) injection gene therapy for the treatment of wet age-related macular degeneration (AMD